KAKEHASHI Inc. is pleased to announce that it has signed an agreement for a Series D round of approximately 14 billion yen in total, with Goldman Sachs as the lead investor, consisting of a third-party allotment of new shares, share transfers by existing shareholders, venture debt and loans.
With this funding, we will further deepen our collaboration with a wide range of players, and actively invest in M&A, new technologies, and human resources with a view to promoting these businesses. We will accelerate the expansion of our platform by strengthening our organizational foundation and expanding our products, and aim to solve Japan’s medical issues through the promotion of next-generation healthcare.
With the mission of “Making the Japanese medical experience flexible,” we have been promoting our business together with medical professionals and partner companies, aiming to create an ecosystem that will serve as the foundation for tomorrow’s healthcare.
こちらもお読みください： BONX WORK、アイホンのVi-nurseシステムと統合
We develop and provide multiple products for pharmacies, including “Musubi,” a cloud-based electronic medical history and medication instruction tool launched in 2017, and the group as a whole covers more than 20% of pharmacies in Japan, more than 14,000 stores nationwide. It has become the medical platform service of choice to promote the “next-generation of pharmacies,” which is being called into question in recent years due to the revision of the Pharmaceutical and Medical Device Act and the revision of medical treatment fees, and we have received many examples of strengthening the relationship between patients and pharmacists, improving medication adherence, and improving pharmacy management. Most recently, we have been selected for the Ministry of Economy, Trade and Industry’s “Demonstration Research Project for Promoting the Use of PHR in Medical Institutions,” and have been steadily achieving results in both technical research and social implementation, such as joint research with medical institutions and universities.
Going forward, in addition to expanding our services for pharmacies, we intend to continue working to solve medical issues through the reinvention of healthcare by broadening our horizons to the entire pharmaceutical and medical industries together with pharmacies, such as maximizing the value of treatment and medicines through intervention and follow-up with patients, utilizing PHRs to promote the health and maximize QOL of consumers beyond prescription drugs, optimizing pharmaceutical distribution and stabilizing supply through collaboration with pharmacies, wholesalers, pharmaceutical manufacturers, etc. In order to realize such wide-ranging collaboration, we will actively invest in M&A and new technologies to further accelerate the speed of problem-solving.
ソース PRタイムズ
